OnKure Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule precision medicines that selectively target specific cancer-driving mutations while sparing normal proteins, designed to improve efficacy and reduce toxicity compared to non-selective inhibitors. Its lead program, OKI-219, is a highly selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) mutations found in a significant portion of breast cancers and other solid tumors, currently in Phase 1 clinical trials evaluating monotherapy and combination regimens. The company generates value by advancing drugs through the development pipeline toward regulatory approval and potential commercialization in large cancer markets where existing therapies cause substantial side effects.